Kyverna Therapeutics, Inc.
KYTX
$8.17
$0.091.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -43.18M | -43.18M | -35.82M | -11.10M | -12.36M |
| Gross Profit | 43.18M | 43.18M | 35.82M | 11.10M | 12.36M |
| SG&A Expenses | 43.60M | 37.43M | 36.11M | 34.40M | 35.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 158.93M | 163.79M | 169.83M | 171.59M | 171.63M |
| Operating Income | -158.93M | -163.79M | -169.83M | -171.59M | -171.63M |
| Income Before Tax | -152.64M | -156.40M | -161.31M | -160.99M | -158.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -152.64 | -156.40 | -161.31 | -160.99 | -158.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -152.64M | -156.40M | -161.31M | -160.99M | -158.70M |
| EBIT | -158.93M | -163.79M | -169.83M | -171.59M | -171.63M |
| EBITDA | -233.64M | -238.41M | -244.30M | -207.58M | -207.47M |
| EPS Basic | -2.94 | -3.28 | -3.66 | -3.72 | -3.67 |
| Normalized Basic EPS | -1.83 | -2.05 | -2.28 | -2.33 | -2.30 |
| EPS Diluted | -2.94 | -3.28 | -3.66 | -3.72 | -3.67 |
| Normalized Diluted EPS | -1.83 | -2.05 | -2.28 | -2.33 | -2.30 |
| Average Basic Shares Outstanding | 211.90M | 194.23M | 177.01M | 173.09M | 172.83M |
| Average Diluted Shares Outstanding | 211.90M | 194.23M | 177.01M | 173.09M | 172.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |